Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 5/2016

01-05-2016 | Review

ANRIL: a pivotal tumor suppressor long non-coding RNA in human cancers

Authors: Zheng Li, Xin Yu, Jianxiong Shen

Published in: Tumor Biology | Issue 5/2016

Login to get access

Abstract

Long non-coding RNAs (lncRNAs) are a family of non-protein-coding RNAs with length more than 200 nucleotides. LncRNAs played important roles in many biological processes such as cell development, proliferation, invasion and migration. Deregulation of LncRNAs was found in multiple tumors where they can act as a tumor suppressor gene or oncogene. LncRNA ANRIL was identified as an oncogene involved in a number of tumors such as gastric cancer, lung cancer, hepatocellular carcinoma, and esophageal squamous cell carcinoma. Inhibition of ANRIL suppressed the cancer cell proliferation, migration and invasion. Increasing data has showed that ANRIL may act as a diagnostic and prognostic biomarker for some tumors. In our review, we summarize an overview of current knowledge concerning the expression and role of ANRIL in various cancers.
Literature
1.
2.
Wan X, Ding X, Chen S, Song H, Jiang H, Fang Y, et al. The functional sites of miRNAs and lncRNAs in gastric carcinogenesis. Tumour Biol. 2015;36:521–32.CrossRefPubMedPubMedCentral
3.
4.
Li CH, Chen Y. Targeting long non-coding RNAs in cancers: progress and prospects. Int J Biochem Cell Biol. 2013;45:1895–910.CrossRefPubMed
5.
Kitagawa M, Kotake Y, Ohhata T. Long non-coding RNAs involved in cancer development and cell fate determination. Curr Drug Targets. 2012;13:1616–21.CrossRefPubMed
6.
7.
Taylor DH, Chu ET, Spektor R, Soloway PD. Long non-coding RNA regulation of reproduction and development. Mol Reprod Dev. 2015. doi:10.​1002/​mrd.​22581.
8.
9.
10.
11.
Yu X, Li Z. MicroRNA expression and its implications for diagnosis and therapy of tongue squamous cell carcinoma. J Cell Mol Med. 2015. doi:10.​1111/​jcmm.​12650.
12.
13.
14.
Yu X, Li Z. Long non-coding RNA HOTAIR: a novel oncogene (review). Mol Med Rep. 2015;12:5611–8.PubMed
15.
16.
Wang G, Liu C, Deng S, Zhao Q, Li T, Qiao S, et al. Long noncoding rnas in regulation of human breast cancer. Brief Funct Genomics. 2015. doi:10.​1093/​bfgp/​elv049.
17.
Tao H, Yang JJ, Zhou X, Deng ZY, Shi KH, Li J. Emerging role of long non-coding RNAs in lung cancer: current status and future prospects. Respir Med. 2015;110:12–9. 
18.
Meseure D, Drak Alsibai K, Nicolas A, Bieche I, Morillon A. Long non-coding RNAs as new architects in cancer epigenetics, prognostic biomarkers, and potential therapeutic targets. Biomed Res Int. 2015;2015:320214.CrossRefPubMedPubMedCentral
19.
Shahryari A, Jazi MS, Samaei NM, Mowla SJ. Long non-coding RNA SOX2OT: expression signature, splicing patterns, and emerging roles in pluripotency and tumorigenesis. Front Genet. 2015;6:196.CrossRefPubMedPubMedCentral
20.
Ding X, Wan X, Jiang H, Song H, Fang Y, Chen S, et al. The clinical value of ncRNAs in gastric cancer: a systematic review and meta-analyses. Tumour Biol. 2015;36:4017–25.CrossRefPubMed
21.
22.
Yang X, Xie X, Xiao YF, Xie R, Hu CJ, Tang B, et al. The emergence of long non-coding RNAs in the tumorigenesis of hepatocellular carcinoma. Cancer Lett. 2015;360:119–24.CrossRefPubMed
23.
Martens-Uzunova ES, Bottcher R, Croce CM, Jenster G, Visakorpi T, Calin GA. Long non-coding RNA in prostate, bladder, and kidney cancer. Eur Urol. 2014;65:1140–51.CrossRefPubMed
24.
25.
26.
Pasmant E, Laurendeau I, Heron D, Vidaud M, Vidaud D, Bieche I. Characterization of a germ-line deletion, including the entire INK4/ARF locus, in a melanoma-neural system tumor family: identification of ANRIL, an antisense non-coding RNA whose expression coclusters with ARF. Cancer Res. 2007;67:3963–9.CrossRefPubMed
27.
Zhang EB, Kong R, Yin DD, You LH, Sun M, Han L, et al. Long non-coding RNA ANRIL indicates a poor prognosis of gastric cancer and promotes tumor growth by epigenetically silencing of mir-99a/mir-449a. Oncotarget. 2014;5:2276–92.CrossRefPubMedPubMedCentral
28.
Iranpour M, Soudyab M, Geranpayeh L, Mirfakhraie R, Azargashb E, Movafagh A, et al. Expression analysis of four long non-coding RNAs in breast cancer. Tumour Biol. 2015. doi:10.​1007/​s13277-015-4135-2.
29.
Naemura M, Murasaki C, Inoue Y, Okamoto H, Kotake Y. Long non-coding RNA ANRIL regulates proliferation of non-small-cell lung cancer and cervical cancer cells. Anticancer Res. 2015;35:5377–82.PubMed
30.
Zhu H, Li X, Song Y, Zhang P, Xiao Y, Xing Y. Long non-coding RNA ANRIL is upregulated in bladder cancer and regulates bladder cancer cell proliferation and apoptosis through the intrinsic pathway. Biochem Biophys Res Commun. 2015;467:223–8.CrossRefPubMed
31.
Kia SK, Gorski MM, Giannakopoulos S, Verrijzer CP. SWI/SNF mediates polycomb eviction and epigenetic reprogramming of the INK4b-ARF-INK4a locus. Mol Cell Biol. 2008;28:3457–64.CrossRefPubMedPubMedCentral
32.
Gil J, Peters G. Regulation of the INK4b-ARF-INK4a tumour suppressor locus: all for one or one for all. Nat Rev Mol Cell Biol. 2006;7:667–77.CrossRefPubMed
33.
Ozenne P, Eymin B, Brambilla E, Gazzeri S. The ARF tumor suppressor: structure, functions and status in cancer. Int J Cancer. 2010;127:2239–47.CrossRefPubMed
34.
Kheradmand Kia S, Solaimani Kartalaei P, Farahbakhshian E, Pourfarzad F, von Lindern M, Verrijzer CP. EZH2-dependent chromatin looping controls INK4a and INK4b, but not ARF, during human progenitor cell differentiation and cellular senescence. Epigenetics Chromatin. 2009;2:16.CrossRefPubMedPubMedCentral
35.
Yap KL, Li S, Munoz-Cabello AM, Raguz S, Zeng L, Mujtaba S, et al. Molecular interplay of the non-coding RNA ANRIL and methylated histone H3 lysine 27 by polycomb CBX7 in transcriptional silencing of INK4a. Mol Cell. 2010;38:662–74.CrossRefPubMedPubMedCentral
36.
Aguilo F, Di Cecilia S, Walsh MJ. Long non-coding RNA ANRIL and polycomb in human cancers and cardiovascular disease. Curr Top Microbiol Immunol. 2015. doi:10.​1007/​82_​2015_​455.
37.
He S, Gu W, Li Y, Zhu H. ANRIL/CDKN2B-AS shows two-stage clade-specific evolution and becomes conserved after transposon insertions in simians. BMC Evol Biol. 2013;13:247.CrossRefPubMedPubMedCentral
38.
39.
Kotake Y, Nakagawa T, Kitagawa K, Suzuki S, Liu N, Kitagawa M, et al. Long non-coding RNA ANRIL is required for the PRC2 recruitment to and silencing of p15(INK4b) tumor suppressor gene. Oncogene. 2011;30:1956–62.CrossRefPubMed
40.
Rodriguez C, Borgel J, Court F, Cathala G, Forne T, Piette J. CTCF is a DNA methylation-sensitive positive regulator of the INK/ARF locus. Biochem Biophys Res Commun. 2010;392:129–34.CrossRefPubMed
41.
Nie FQ, Sun M, Yang JS, Xie M, Xu TP, Xia R, et al. Long non-coding RNA ANRIL promotes non-small cell lung cancer cell proliferation and inhibits apoptosis by silencing KLF2 and p21 expression. Mol Cancer Ther. 2015;14:268–77.CrossRefPubMed
42.
Lin L, Gu ZT, Chen WH, Cao KJ. Increased expression of the long non-coding RNA ANRIL promotes lung cancer cell metastasis and correlates with poor prognosis. Diagn Pathol. 2015;10:14.CrossRefPubMedPubMedCentral
43.
Kang YH, Kim D, Jin EJ. Down-regulation of phospholipase d stimulates death of lung cancer cells involving upregulation of the long ncRNA anril. Anticancer Res. 2015;35:2795–803.PubMed
44.
Huang MD, Chen WM, Qi FZ, Xia R, Sun M, Xu TP, et al. Long non-coding RNA ANRIL is upregulated in hepatocellular carcinoma and regulates cell apoptosis by epigenetic silencing of klf2. J Hematol Oncol. 2015;8:50.CrossRefPubMedPubMedCentral
45.
Hua L, Wang CY, Yao KH, Chen JT, Zhang JJ, Ma WL. High expression of long non-coding RNA ANRIL is associated with poor prognosis in hepatocellular carcinoma. Int J Clin Exp Pathol. 2015;8:3076–82.PubMedPubMedCentral
46.
Chen D, Zhang Z, Mao C, Zhou Y, Yu L, Yin Y, et al. ANRIL inhibits p15(INK4b) through the TGF beta 1 signaling pathway in human esophageal squamous cell carcinoma. Cell Immunol. 2014;289:91–6.CrossRefPubMed
47.
Kang M, Sang Y, Gu H, Zheng L, Wang L, Liu C, et al. Long non-coding RNAs POLR2Ee rs3787016 c/t and HULC rs7763881 A/C polymorphisms are associated with decreased risk of esophageal cancer. Tumour Biol. 2015;36:6401–8.CrossRefPubMed
48.
Martinez-Fernandez M, Feber A, Duenas M, Segovia C, Rubio C, Fernandez M, et al. Analysis of the polycomb-related lncRNAs HOTAIR and ANRIL in bladder cancer. Clin Epigenetics. 2015;7:109.CrossRefPubMedPubMedCentral
49.
Qiu JJ, Lin YY, Ding JX, Feng WW, Jin HY, Hua KQ. Long non-coding RNA ANRIL predicts poor prognosis and promotes invasion/metastasis in serous ovarian cancer. Int J Oncol. 2015;46:2497–505.PubMed
50.
Iacobucci I, Sazzini M, Garagnani P, Ferrari A, Boattini A, Lonetti A, et al. A polymorphism in the chromosome 9p21 ANRIL locus is associated to Philadelphia positive acute lymphoblastic leukemia. Leuk Res. 2011;35:1052–9.CrossRefPubMed
51.
Pasmant E, Sabbagh A, Masliah-Planchon J, Ortonne N, Laurendeau I, Melin L, et al. Role of non-coding RNA ANRIL in genesis of plexiform neurofibromas in neurofibromatosis type 1. J Natl Cancer Inst. 2011;103:1713–22.CrossRefPubMed
52.
Mussotter T, Kluwe L, Hogel J, Nguyen R, Cooper DN, Mautner VF, et al. Non-coding RNA ANRIL and the number of plexiform neurofibromas in patients with NF1 microdeletions. BMC Med Genet. 2012;13:98.CrossRefPubMedPubMedCentral
Metadata
Title
ANRIL: a pivotal tumor suppressor long non-coding RNA in human cancers
Authors
Zheng Li
Xin Yu
Jianxiong Shen
Publication date
01-05-2016
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 5/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-016-4808-5

Other articles of this Issue 5/2016

Tumor Biology 5/2016 Go to the issue

Original Article

Desacetyl nimbinene inhibits breast cancer growth and metastasis through reactive oxygen species mediated mechanisms

Original Article

17-DMAG induces heat shock protein 90 functional impairment in human bladder cancer cells: knocking down the hallmark traits of malignancy

Original Article

Breast cancer cell line MDA-MB-231 miRNA profile expression after BIK interference: BIK involvement in autophagy

Original Article

Comparative analysis of basaloid and conventional squamous cell carcinomas of the esophagus: prognostic relevance of clinicopathological features and protein expression

Original Article

The construction and proliferative effects of a lentiviral vector capable of stably overexpressing SPINK1 gene in human pancreatic cancer AsPC-1 cell line

Original Article

Cooperative effect of BI-69A11 and celecoxib enhances radiosensitization by modulating DNA damage repair in colon carcinoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits